These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37651273)

  • 61. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?
    Knopman DS; Hershey L
    Neurology; 2023 Oct; 101(14):610-620. PubMed ID: 37295957
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
    Retout S; Gieschke R; Serafin D; Weber C; Frey N; Hofmann C
    Clin Pharmacol Ther; 2022 Apr; 111(4):857-866. PubMed ID: 35100444
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease.
    Ryan NS; Lashley T; Revesz T; Dantu K; Fox NC; Morris HR
    J Alzheimers Dis; 2015; 44(4):1069-74. PubMed ID: 25408217
    [TBL] [Abstract][Full Text] [Related]  

  • 66. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function.
    Xiong M; Jiang H; Serrano JR; Gonzales ER; Wang C; Gratuze M; Hoyle R; Bien-Ly N; Silverman AP; Sullivan PM; Watts RJ; Ulrich JD; Zipfel GJ; Holtzman DM
    Sci Transl Med; 2021 Feb; 13(581):. PubMed ID: 33597265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease.
    Høilund-Carlsen PF; Revheim ME; Alavi A; Barrio JR
    Clin Nucl Med; 2023 Aug; 48(8):689-691. PubMed ID: 37314733
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
    Andreasen N; Simeoni M; Ostlund H; Lisjo PI; Fladby T; Loercher AE; Byrne GJ; Murray F; Scott-Stevens PT; Wallin A; Zhang YY; Bronge LH; Zetterberg H; Nordberg AK; Yeo AJ; Khan SA; Hilpert J; Mistry PC
    PLoS One; 2015; 10(3):e0098153. PubMed ID: 25789616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials.
    Høilund-Carlsen PF; Revheim ME; Alavi A; Satyamurthy N; Barrio JR
    J Alzheimers Dis; 2022; 90(4):1395-1399. PubMed ID: 36278356
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.
    Barkhof F; Daams M; Scheltens P; Brashear HR; Arrighi HM; Bechten A; Morris K; McGovern M; Wattjes MP
    AJNR Am J Neuroradiol; 2013 Aug; 34(8):1550-5. PubMed ID: 23436056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Pittock RR; Aakre JA; Castillo AM; Ramanan VK; Kremers WK; Jack CR; Vemuri P; Lowe VJ; Knopman DS; Petersen RC; Graff-Radford J; Vassilaki M
    Neurology; 2023 Nov; 101(19):e1837-e1849. PubMed ID: 37586881
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
    Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L
    Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
    Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
    Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.
    VandeVrede L; Gibbs DM; Koestler M; La Joie R; Ljubenkov PA; Provost K; Soleimani-Meigooni D; Strom A; Tsoy E; Rabinovici GD; Boxer AL
    Alzheimers Dement (Amst); 2020; 12(1):e12101. PubMed ID: 33072846
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
    Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
    Geerts H; Walker M; Rose R; Bergeler S; van der Graaf PH; Schuck E; Koyama A; Yasuda S; Hussein Z; Reyderman L; Swanson C; Cabal A
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):444-461. PubMed ID: 36632701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.